Immunitybio Inc (IBRX) - Total Liabilities
Based on the latest financial reports, Immunitybio Inc (IBRX) has total liabilities worth $569.82 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Immunitybio Inc (IBRX) equity growth momentum to track the company's year-over-year net asset growth rate.
Immunitybio Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Immunitybio Inc's total liabilities have evolved over time, based on quarterly financial data.
Immunitybio Inc Competitors by Total Liabilities
The table below lists competitors of Immunitybio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kion Group AG
XETRA:KGX
|
Germany | €12.72 Billion |
|
Guangzhou Automobile Group Co Ltd Class A
SHG:601238
|
China | CN¥96.48 Billion |
|
Chord Energy Corp
NASDAQ:CHRD
|
USA | $5.02 Billion |
|
Kingfa Sci&Tech Co Ltd
SHG:600143
|
China | CN¥42.31 Billion |
|
Huaibei Mining Holdings Co Ltd
SHG:600985
|
China | CN¥43.47 Billion |
|
Shan Dong Sun Paper Industry Joint Stock Co Ltd
SHE:002078
|
China | CN¥28.55 Billion |
|
Nestle (Malaysia) Bhd
KLSE:4707
|
Malaysia | RM2.96 Billion |
|
WPG Holdings Ltd
TW:3702
|
Taiwan | NT$386.87 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Immunitybio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IBRX stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunitybio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunitybio Inc (2013–2024)
The table below shows the annual total liabilities of Immunitybio Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $871.06 Million | -20.11% |
| 2023-12-31 | $1.09 Billion | +34.26% |
| 2022-12-31 | $812.18 Million | +13.94% |
| 2021-12-31 | $712.82 Million | +109.73% |
| 2020-12-31 | $339.87 Million | +1414.31% |
| 2019-12-31 | $22.44 Million | -37.56% |
| 2018-12-31 | $35.94 Million | +13.76% |
| 2017-12-31 | $31.60 Million | +31.22% |
| 2016-12-31 | $24.08 Million | +121.84% |
| 2015-12-31 | $10.85 Million | +351.31% |
| 2014-12-31 | $2.40 Million | -51.88% |
| 2013-12-31 | $5.00 Million | -- |
About Immunitybio Inc
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therap… Read more